The Future In Our Hands: Screening For Preclinical Alzheimer's Disease By Analysing Hand Movements
Funder
National Health and Medical Research Council
Funding Amount
$899,782.00
Summary
Alzheimer's disease (AD) starts damaging the brain 10-20 years before memory problems begin. By the time of diagnosis, it is hard to treat because the damage is so severe. We need a way to detect AD much earlier. We will develop a simple new computer test to detect early signs of AD by recording and analysing hand movements. Then people can start prevention earlier and scientists can research better treatments to improve people's quality of life and reduce the number of people with dementia.
ASCAPE: Audio App-delivered Screening For Cognition And Age-related Health In Older Prisoners
Funder
National Health and Medical Research Council
Funding Amount
$844,050.00
Summary
This study aims to develop and test a new, innovative health screening app to examine the health and functioning of older, ageing prisoners in Australia. The app will deliver a range of health and functioning measures via audio, minimising the need for literacy skills and for staff supervision during testing. It is hoped that this app will be easily implemented in prisons in future, to enable better health management for this growing cohort with complex health needs.
Targeting Pathogenic TAR DNA-binding Protein 43 To Treat Frontotemporal Dementia And Motor Neuron Disease
Funder
National Health and Medical Research Council
Funding Amount
$687,444.00
Summary
Frontotemporal dementia and motor neuron Disease are rapidly progressive and fatal neurodegenerative diseases that affect people in their prime. Poor understanding of the processes that lead to these diseases have slowed drug development. Through innovative experimental design, we aim to decipher a novel disease mechanism that involves specific molecular interactions and translate these findings into new therapies for the diseases.
Using A National Level Multi-registry Analysis To Determine Whether Prescribed Anti-platelet Therapies Post-stroke Can Modify The Risk Of Cognitive Decline Or Dementia
Funder
National Health and Medical Research Council
Funding Amount
$446,302.00
Summary
Stroke survivors are at risk of dementia. Blood brain barrier damage after stroke may allow drugs in the bloodstream, which can be toxic to brain cells, to enter the brain. Clopidogrel, a drug commonly used after stroke, blocks a receptor essential for brain repair. After stroke, clopidogrel may access the brain and compromise repair processes, increasing the risk of dementia. We will link use of clopidogrel to the risk of dementia after stroke, using national Swedish health registry data.